sweelin® is FDA GRAS approved as general sweetener

The U.S. FDA has completed its review of the GRAS (Generally Recognized as Safe) notice for sweelin® and confirmed it has no safety concerns regarding the use of sweelin® as a general sweetener, according to Amai Proteins. The GRAS Notice was submitted just nine months ago.

sweelin® is a next-generation sweet protein that enables significant sugar reduction and replaces conventional sweeteners with a protein-based alternative, designed to deliver superior clean taste, competitive cost, and improved formulation performance, the company said.

Amai Proteins can now move quickly to run product trials and accelerate sales and market adoption with U.S. Food and Beverage customers.

This milestone builds on other groundbreaking developments for sweelin®:

1.  The world's First Clinical Trial on a Sweet Protein: Amai Proteins completed a clinical study demonstrating that sweelin® does not impact blood glucose or insulin levels. 

2.  Clean Label and consumer-friendly: sweelin® can be labeled as "Serendipity Berry Sweet Protein", as confirmed by legal counsel. This means manufacturers can use sweelin® inside products with simple, and easily understandable ingredient lists (no artificial additives, E-numbers, or complex chemical names) appealing to health-conscious consumers and aligning with today's Clean Label trend. 

(Photo: Dreamstime.com)

These achievements make sweelin® a high-potential and safe protein sweetener that also fits with the strong trend of protein-focused and GLP-1-friendly food and beverage innovations. Its Clean Label compatibility adds extra appeal for both manufacturers and consumers.

"Receiving FDA GRAS notification for sweelin® is a pivotal step for Amai," said Amir Guttman, CEO of Amai Proteins. This milestone validates our regulatory strategy and allows us to move forward with commercialization discussions with partners who are looking for Clean Label, next-generation sweetening solutions."

Amai Proteins is now connecting with investors and partners to leverage these regulatory and clinical milestones for fast market entry and strong growth opportunities.